Super Bowl Victory ...
Health Care: Drugs
Allos Therapeutics Inc. (ALTH: NASDAQ)
$1.73 -0.01 | -0.57%
02/08/12 - 02:35 PM ET
344.42K / 613.30K
Vol / Avg. Vol:1.75 / 1.74
Open / Prev. Close:1.68 - 1.75
Today's Range:1.25 - 3.45
52 Wk Range:22.54%
Performance YTD:TheStreet Rating:
Portfolios with ALTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- Userrab 's
- Usergdean1
- User$5 stocks
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
- UserWatch List - Healthcare / B...
- UserBioTech
Latest ALTH Headlines from TheStreet
- Allos Stock Gaps Down On Today's Open (ALTH) 01.20.12 | 09:01 am
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
- Allos Stock Hits New 52-Week Low (ALTH) 09.09.11 | 10:09 am
- Amag-Allos Merger in Jeopardy 09.07.11 | 06:09 am
Press Releases for ALTH
- Allos Therapeutics Requests Re-Examination Of CHMP Opinion On FOLOTYN® In PTCL At The European Medicines Agency - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Receives Negative Opinion From The CHMP On FOLOTYN - Business Wire 01.20.12 | 07:01 am
- Allos Therapeutics Reports 2011 Financial Highlights And Key Business Priorities - Business Wire 01.10.12 | 08:01 am
- Allos Therapeutics Invites Investors To Listen To Webcast Of Presentation At J.P. Morgan Healthcare Conference - Business Wire 12.21.11 | 08:12 am
- Allos Therapeutics Reports Third Quarter 2011 Financial Results - Business Wire 11.03.11 | 07:11 am
- Allos Therapeutics Announces Termination Of Merger Agreement With AMAG Pharmaceuticals - Business Wire 10.21.11 | 09:10 am
- Allos Therapeutics Announces Settlement With Putative Class Action Plaintiffs Regarding Merger With AMAG Pharmaceuticals - Business Wire 10.13.11 | 07:10 pm
- Allos Therapeutics Continues To Work Toward Completion Of Merger With AMAG Pharmaceuticals - Business Wire 10.10.11 | 08:10 am
- Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc. - Business Wire 09.23.11 | 03:09 pm
Partner Headlines for ALTH
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog - Zacks 02.06.12 | 06:02 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Company News for November 4, 2011 - Corporate Summary - Zacks 11.04.11 | 10:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
- Stocks Rally on European Debt Summit Optimism; December Crude Surges Over 2% - NASDAQ 10.21.11 | 04:10 pm
- Mid-Day Update: Stocks Surge, Indexes Top 1% on Europe Debt Optimism, Earnings - NASDAQ 10.21.11 | 04:10 pm
- Buy And Sell Ideas Based On Monday's Big Biotech News Movers - Seeking Alpha 10.11.11 | 08:10 am
- Morning Market Movers - Benzinga 09.21.11 | 09:09 am
- Allos Therapeutics Evenly Poised - Analyst Blog - Zacks 08.15.11 | 09:08 am
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
